ArticleJournal of the Chinese Medical Association : JCMA2025
Endovascular treatment of patients concurrent with type 3A aortic syndrome and degeneration (infrarenal) abdominal aortic aneurysm.
Article in Journal of the Chinese Medical Association : JCMA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdvances in endovascular treatments have improved surgical outcomes for patients with aortic pathologies. However, for patients with comorbid aortic dissection and degenerative abdominal aortic aneurysm (AAA), effective surgical treatment is often a challenge. Here, we analyzed the outcomes of endovascular treatment in patients who concurrently had acute DeBakey type 3A aortic syndrome and degenerative infrarenal AAA.
methodsFrom 2012 to 2019, 11 patients were diagnosed concurrently with acute type 3A aortic syndrome and degenerative infrarenal AAA that met intervention criteria (typical acute descending aortic dissection, or thickness of hematoma or ulceration greater than 10 mm in intramural hematomas [IMH] or penetrating aortic ulcers [PAU], in addition to AAA diameter >5 cm). Three patients had a typical dissection, three had IMH, and five had PAU.
resultsFour men underwent a one-stage operation, and preoperative cerebrospinal fluid lumbar drainage was instituted in three patients. The other seven patients underwent a two-stage operation consisting of endovascular aneurysm repair (EVAR) followed by thoracic endovascular aortic repair (TEVAR) over a period ranging from 3 to 52 months. Follow-up continued until the end of 2022. No spinal cord ischemia (SCI) was present in either group. In the one-stage group, one patient died of intracranial hemorrhage 1.5 months after the operation. The other three patients did not experience any aortic event requiring reintervention. In the two-stage group, four patients required reintervention, including one type I endoleak, 2 type II endoleaks, and one visceral artery stent compromise. In this group, four patients died during follow-up.
conclusionMid-term outcomes were acceptable in patients with concurrent acute type 3A aortic syndrome and degenerative infra-renal AAA, managed with EVAR and TEVAR, both simultaneously and sequentially. The incidence of SCI was low, and aortic coverage spared the segment from T8 to L1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.